中华现代护理杂志
中華現代護理雜誌
중화현대호리잡지
CHINESE JOURNAL OF MODERN NURSING
2012年
19期
2271-2273
,共3页
护理%依诺肝素%磺达肝癸钠%急性冠脉综合征
護理%依諾肝素%磺達肝癸鈉%急性冠脈綜閤徵
호리%의낙간소%광체간계납%급성관맥종합정
Nursing care%Enoxapar%Fondaparinux%Acute coronary syndrome
目的 比较在75岁以上老年急性冠脉综合征(ACS)患者中应用磺达肝癸钠和依诺肝素的安全性.方法 2009年12月至2011年12月期间,将75岁以上老年ACS患者127例随机分为成对照组(n=63)和观察组(n=64),两组患者均在常规应用ACS药物治疗且无应用抗凝药物禁忌情况下分别应用依诺肝素和磺达肝癸钠,对照组为依诺肝素组,0.75 mg/kg皮下注射,每12小时1次,持续8d;观察组为磺达肝癸钠组,2.5 mg皮下注射,每天1次,持续8d.比较两组患者严重出血(脑出血、腹膜腔出血、呕血、便血++++)及轻度出血(皮下瘀斑、牙龈出血、血尿、便血+++及以下)的发生率.结果 观察组中发生严重出血者1例(1.56％),对照组中发生严重出血者9例(14.29％),两组严重出血率比较差异有统计学意义(x2 =9.141,P=0.003);观察组中发生轻度出血者7例(10.94％),对照组中发生轻度出血者20例(31.75％),两组轻度出血率比较差异有统计学意义(x2 =5.266,P=0.017).结论 75岁以上老年ACS患者应用磺达肝癸钠的出血率低于应用依诺肝素,安全性更高.
目的 比較在75歲以上老年急性冠脈綜閤徵(ACS)患者中應用磺達肝癸鈉和依諾肝素的安全性.方法 2009年12月至2011年12月期間,將75歲以上老年ACS患者127例隨機分為成對照組(n=63)和觀察組(n=64),兩組患者均在常規應用ACS藥物治療且無應用抗凝藥物禁忌情況下分彆應用依諾肝素和磺達肝癸鈉,對照組為依諾肝素組,0.75 mg/kg皮下註射,每12小時1次,持續8d;觀察組為磺達肝癸鈉組,2.5 mg皮下註射,每天1次,持續8d.比較兩組患者嚴重齣血(腦齣血、腹膜腔齣血、嘔血、便血++++)及輕度齣血(皮下瘀斑、牙齦齣血、血尿、便血+++及以下)的髮生率.結果 觀察組中髮生嚴重齣血者1例(1.56％),對照組中髮生嚴重齣血者9例(14.29％),兩組嚴重齣血率比較差異有統計學意義(x2 =9.141,P=0.003);觀察組中髮生輕度齣血者7例(10.94％),對照組中髮生輕度齣血者20例(31.75％),兩組輕度齣血率比較差異有統計學意義(x2 =5.266,P=0.017).結論 75歲以上老年ACS患者應用磺達肝癸鈉的齣血率低于應用依諾肝素,安全性更高.
목적 비교재75세이상노년급성관맥종합정(ACS)환자중응용광체간계납화의낙간소적안전성.방법 2009년12월지2011년12월기간,장75세이상노년ACS환자127례수궤분위성대조조(n=63)화관찰조(n=64),량조환자균재상규응용ACS약물치료차무응용항응약물금기정황하분별응용의낙간소화광체간계납,대조조위의낙간소조,0.75 mg/kg피하주사,매12소시1차,지속8d;관찰조위광체간계납조,2.5 mg피하주사,매천1차,지속8d.비교량조환자엄중출혈(뇌출혈、복막강출혈、구혈、편혈++++)급경도출혈(피하어반、아간출혈、혈뇨、편혈+++급이하)적발생솔.결과 관찰조중발생엄중출혈자1례(1.56％),대조조중발생엄중출혈자9례(14.29％),량조엄중출혈솔비교차이유통계학의의(x2 =9.141,P=0.003);관찰조중발생경도출혈자7례(10.94％),대조조중발생경도출혈자20례(31.75％),량조경도출혈솔비교차이유통계학의의(x2 =5.266,P=0.017).결론 75세이상노년ACS환자응용광체간계납적출혈솔저우응용의낙간소,안전성경고.
Objective To evaluate the incidence of bleeding events and nursing effects of fondaparinux and enoxapar in the treatment of acute coronary syndrome in patients ＞ 75 years of old.Methods Between December 2009 and December 2011,A total of 127 patients ＞75 years of old with acute coronary syndrome and no contraindications for anti-coagulants were randomly assigned to the control group( enoxapar n =63 ) and the observation group( fondaparinux n =64 ).The conventional treatment was added in both group,fondaparinux was added (2.5 mg daily subcutaneously for 8 days) in the observation group,and enoxaparin (0.75 mg/kg twice daily for 8 days) was added in the control group and then we compared the incidence of bleeding events (including severe bleeding and minor bleeding events ) between the two groups.Results The incidence of severe bleeding events in the observation group and control group was 1( 1.56％ ) and 9 ( 14.29％ ),respectively,and the difference had reached statistical significance( x2 =9.141,P =0.003 ).The incidence of minor bleeding in the observational group and control group were 7 (10.94％) and 20(31.75％ ),respectively,and has also reached statistical significance ( x2 =5.266,P =0.017 ).Conclusions In the treatment of acute coronary syndrome patients ＞ 75 years of old,fondaparinux has a lower incidence of bleeding events and thus it is safer than enoxapar.
